Mutations in the omicron variant of the SARS-CoV-2 virus may impact certain molecular tests for COVID-19, the Food and Drug Administration announced yesterday. Specifically, FDA expects a Tide Laboratories test to produce false negative results for the omicron variant and is working with the manufacturer to address the issue. The agency said it does not believe the test is used for high-volume testing, and lists laboratories that perform the test. FDA also identifies certain tests that are less sensitive to a mutation in the omicron variant, but said it does not expect the variant to impact the overall sensitivity of those tests. The update includes recommendations for clinical laboratory staff and health care providers using these tests. 

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday broadened its masking guidance, enabling visitors of health care facilities to wear N95 masks.…
Headline
Pfizer yesterday asked the Food and Drug Administration to authorize a second booster dose of its COVID-19 vaccine for adults age 65 and older who…
Headline
Weekly COVID-19-associated hospitalization rates among U.S. infants and children under age 5 have declined since peaking Jan. 8, but peak rates during omicron…
Headline
The Food and Drug Administration recently authorized extending from six to nine months the shelf life for refrigerated Johnson & Johnson COVID-19…
Headline
The Transportation Security Administration will continue to require masks on public transportation through April 18 to protect against COVID-19, as the Centers…
Headline
In a study of 1,364 children aged 5-15, two doses of the Pfizer COVID-19 vaccine reduced the risk of omicron infection by 31% in those under 12 and 59% in…